A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

eCential Robotics and ChoiceSpine Announce Long-Term Partnership to Enhance Robotic Spine Implant Surgery

eCential Robotics, a French growth company that designs, manufactures, and markets the first unified 2D/3D robotic imaging and surgical navigation system for bone surgery indications and ChoiceSpine LLC, a US privately-held spinal implant company, announced today their long-term partnership to offer a common optimized solution. This system combines navigation, robotics, and implant systems that are easy to use, accurate for spine surgeons, and benefits the patient.

Combining innovative technologies and strengths

After starting the process in 2021, eCential Robotics and ChoiceSpine agreed to partner their technologies with spine robotic surgeries. Built on the technical excellence of the products and a common long-term vision, a collaboration combining two critical assets is emerging:

eCential Robotics’ Platform

The eCential Robotics platform pulls together intraoperative 2D/3D imaging, navigation, and robotics in its core design as the only available fully-unified, single-device solution with a single-user interface. In addition, the eCential Robotics platform is an open solution, catering to different surgeons’ preferences. Built around a range of applications (“Apps”) currently dedicated to spine surgery, there are plans for multiple bone surgery indications soon.

ChoiceSpine LLC Offerings

ChoiceSpine is a spinal implant company with a robust, comprehensive hardware and orthobiologics portfolio. The Knoxville-based company is recognized for introducing innovative and niche solutions to the spinal implant market, emphasizing MIS solutions, such as the Thunderbolt™ Minimally Invasive Pedicle Screw System and the Triton™ 3D printed SI Joint Fixation System. Other differentiating technologies offered by ChoiceSpine include proprietary BioBond™ 3D printed interbodies, a shallow docking access system for direct lateral surgery, and multiple cervical fusion options. In addition, the orthobiologics portfolio offers bone graft solutions, including 100% demineralized bone matrix, cortical fibers, synthetics, a cellular bone matrix, structural allograft, and allograft sponge options.

Taking full advantage of ChoiceSpine implant solutions using eCential Robotics’ unified platform

Navigation and robotics will make it possible to fully utilize the specific features of ChoiceSpine’s portfolio and offer optimization of the surgical procedure. It also brings spine surgeons and patients the benefits of the latest advances in navigation, robotics, and implant technologies.

“By enabling eCential Robotics’ platform to navigate ChoiceSpine implants with our robotic arm, we will optimize and add value to our unified and universal solution for the benefit of surgeons and patients,” said Mrs. Laurence Chabanas, eCential Robotics Chief Strategy Officer. “This partnership is a part of eCential Robotics’ open model strategy. Since our ambition is to offer a unique platform for bone surgery in the operating room and become a standard, we are open to collaborating with implant companies to combine our technologies and offer optimized navigation and robotics for the implementation proposed to the patient,” she added.

Steve Ainsworth, PhD, ChoiceSpine’s EVP of Strategy and Technology, said: “This combination of our innovative cultures will allow us to expand our clinical value by fully encompassing the surgical experience. We believe the eCential Robotics platform, in conjunction with our comprehensive spinal implant and orthobiologics portfolios, will lead the way in advancing spine surgery. This partnership is just one example of how ChoiceSpine brings technically superior spinal devices to the market and is doing spine the right way.”

Initiate eCential Robotics penetration of the US market

After receiving FDA 510(k) clearance of its unified platform’s 2D/3D robotic imaging technology in 2021, eCential Robotics has conducted pre-clinical evaluation tests in the USA, in Q1 2022, with neurosurgeons and orthopedic surgeons. In addition, it has launched the process to obtain clearance for its navigation and collaborative robot (CoBot) device. To support the penetration of the North American market, an eCential Robotics, Inc. subsidiary was created in December 2020.

“This close cooperation with a US company provides eCential Robotics with access to complementary technologies and allows us to initiate and expand our footprint in the US market,” declared Mrs. Laurence Chabanas, eCential Robotics Chief Strategy Officer.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy